Who Exports Celecoxib from India — 326 Suppliers Behind a $133.6M Market
India's celecoxib export market is supplied by 326 active exporters who collectively shipped $133.6M across 4,880 shipments. UMEDICA LABORATORIES PRIVATE LIMITED leads with a 18.6% market share, followed by MACLEODS PHARMACEUTICALS LTD and ALEMBIC PHARMACEUTICALS LIMITED. The top 5 suppliers together control 55.8% of total export value, reflecting a moderately competitive market structure.
Top Celecoxib Exporters from India — Ranked by Export Value
UMEDICA LABORATORIES PRIVATE LIMITED is the leading celecoxib exporter from India, holding a 18.6% share of the $133.6M market across 4,880 shipments from 326 exporters. The top 5 suppliers — UMEDICA LABORATORIES PRIVATE LIMITED, MACLEODS PHARMACEUTICALS LTD, ALEMBIC PHARMACEUTICALS LIMITED, CIPLA LIMITED, MICRO LABS LIMITED — collectively control 55.8% of total export value, indicating a moderately concentrated market. Individual shares are: UMEDICA LABORATORIES PRIVATE LIMITED (18.6%), MACLEODS PHARMACEUTICALS LTD (13.9%), ALEMBIC PHARMACEUTICALS LIMITED (9.1%), CIPLA LIMITED (9.1%), MICRO LABS LIMITED (5.1%).
Top Celecoxib Exporters from India
Ranked by export value · 326 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | UMEDICA LABORATORIES PRIVATE LIMITED CELECOXIB CAPSULES 100MG [PACK OF 500 CAPSULES]CELECOXIB CAPSULE 200 MG_100S_AP_USCELECOXIB 200MG 50X10S CAP AP CHL | $24.8M | 2 | 18.6% |
| 2 | MACLEODS PHARMACEUTICALS LTD CELECOXIB CAPSULES 100MG [PACK OF 500 CAPSULES]CELECOXIB CAPSULE 200 MG_100S_AP_USCELEBIB 200 1 | $18.6M | 21 | 13.9% |
| 3 | ALEMBIC PHARMACEUTICALS LIMITED CELECOXIB CAPSULES 100MG [PACK OF 500 CAPSULES]CELECOXIB CAPSULE 200 MG_100S_AP_USCELECOXIB 200MG 50X10S CAP AP CHL | $12.2M | 6 | 9.1% |
| 4 | CIPLA LIMITED CELECOXIB CAPSULES 100MG [PACK OF 500 CAPSULES]CELECOXIB CAPSULE 200 MG_100S_AP_USCELEDOL 100MG CAPSULES (350 | $12.2M | 3 | 9.1% |
| 5 | MICRO LABS LIMITED CELECOXIB CAPSULES 100MG [PACK OF 500 CAPSULES]PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, SAPHLECOX 200PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, SAPHLECOX-400 | $6.8M | 19 | 5.1% |
| 6 | BDH HEALTHCARE PRIVATE LIMITED PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, SAPHLECOX 200PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, SAPHLECOX-400 | $3.7M | 1 | 2.8% |
| 7 | ZYDUS LIFESCIENCES LIMITED CELECOXIB CAPSULES 100MG CELECOXIB 10X10CELEBID 200 )ZYCEL 200MG CAPSULESCELECOXIB10X10 | $3.6M | 15 | 2.7% |
| 8 | VINS INTERNATIONAL PRIVATE LIMITED PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, SAPHLECOX 200PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, SAPHLECOX-400 | $3.3M | 1 | 2.5% |
| 9 | APOTEX RESEARCH PRIVATE LIMITED APO-CELECOXIB CAP 200MG 100 BTL 53810/77MINT CELECOXIB CAPS 200MG 100'S CANADAMINT CELECOXIB CAPS 100MG 100'S CANADA | $3.2M | 3 | 2.4% |
| 10 | STRIDES PHARMA SCIENCE LIMITED CELECOXIB-WGR CELECOXIB CAPSULES 200MGAPX-CELECOXIB CELECOXIB CAPSULES 200MG 178051.00 X 3X10SCELECOXIB-WGR CELECOXIB CAPSULES 100MG | $2.8M | 2 | 2.1% |
| 11 | SUN PHARMACEUTICAL INDUSTRIES LIMITED CELEBID 200 )CELEBID 200 (CELEBID 200 | $2.8M | 9 | 2.1% |
| 12 | EMCURE PHARMACEUTICALS LIMITED APO-CELECOXIB CAP 200MG 100 BTL 53810/77MINT CELECOXIB CAPS 200MG 100'S CANADAMINT CELECOXIB CAPS 100MG 100'S CANADA | $2.3M | 1 | 1.7% |
| 13 | BDH INDUSTRIES LIMITED PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, SAPHLECOX 200PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, SAPHLECOX-400 | $2.2M | 1 | 1.7% |
| 14 | IPCA LABORATORIES LIMITED CELEDOL 100MG CAPSULES (350 | $2.1M | 1 | 1.5% |
| 15 | GRACURE PHARMACEUTICALS LIMITED PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, SAPHLECOX 200PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, SAPHLECOX-400CELEBIB 200 1 | $1.9M | 8 | 1.4% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Celecoxib exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Alembic Pharmaceuticals Limited | Approved | Yes (July 2025) | Unknown | 223 | Received multiple FDA approvals between 2024 and 2025; WHO-GMP certified as of J |
| Zydus Lifesciences Limited | Approved | Unknown | Unknown | Unknown | Received FDA approval for enzalutamide tablets in October 2024. |
| Emcure Pharmaceuticals Limited | Warning Letter (January 2 | Unknown | Unknown | Unknown | Received FDA warning letter for Hinjawadi facility in January 2022. |
| Intas Pharmaceuticals Limited | Approved | Unknown | Unknown | 89 | Accord Healthcare, a subsidiary, has 89 FDA-approved ANDAs as of August 2018. |
TransData Nexus reviewed the regulatory standing of 4 leading Celecoxib exporters from India. 3 hold US FDA facility approvals, 1 maintain WHO-GMP certification, and 0 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Celecoxib sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for active pharmaceutical ingredient (API) manufacturing. The city's well-established infrastructure, coupled with a skilled workforce and supportive government policies, has attracted numerous pharmaceutical companies specializing in API production. This concentration facilitates efficient production and distribution of APIs like Celecoxib, ensuring a robust supply chain for both domestic and international markets.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Companies such as Alembic Pharmaceuticals, headquartered in Vadodara, have a significant presence in this region. Alembic Pharmaceuticals, established in 1907, manufactures and markets a wide range of pharmaceutical products, including APIs and formulations. The company's extensive experience and infrastructure in the region contribute to the efficient production and export of formulations like Celecoxib.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for pharmaceutical products. Mumbai, being a major port city, provides logistical advantages for companies exporting pharmaceuticals. Cipla Limited, headquartered in Mumbai, is a prominent player in the pharmaceutical industry. Founded in 1935, Cipla focuses on developing medications for various medical conditions, including arthritis, which Celecoxib is commonly used to treat. The company's strategic location facilitates efficient export operations, contributing to the significant share of Celecoxib exports to destinations like the United States.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a pharmaceutical manufacturing hub, largely due to favorable tax incentives and supportive government policies. These incentives have attracted numerous pharmaceutical companies to set up manufacturing units in the area, enhancing production capacities and contributing to the overall pharmaceutical output, including drugs like Celecoxib.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different pharmaceutical clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and compliance records of suppliers, such as UMEDICA LABORATORIES PRIVATE LIMITED and MACLEODS PHARMACEUTICALS LTD, to ensure consistent quality and supply.
- Leverage Export Hubs: Utilize the logistical advantages of export gateways like Mumbai for efficient shipping and distribution to key markets, including the United States and the Philippines.
- Monitor Regulatory Compliance: Stay updated on regulatory changes and ensure that suppliers adhere to international standards to maintain uninterrupted supply chains.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Celecoxib exporters from India
Alembic Pharmaceuticals Limited — Alembic Pharmaceuticals merges with Aleor Dermaceuticals
Alembic Pharmaceuticals Limited completed the amalgamation of Aleor Dermaceuticals Limited, following approval from the National Company Law Tribunal, Ahmedabad Bench. - IMPACT: This merger is expected to enhance Alembic's dermatology portfolio, potentially influencing its overall export capabilities, including Celecoxib.
Impact: This merger is expected to enhance Alembic's dermatology portfolio, potentially influencing its overall export capabilities, including Celecoxib.
Cipla Limited — Cipla acquires Ivia Beaute’s personal care brands
Cipla Limited acquired the distribution and marketing business of Ivia Beaute Pvt Ltd for ₹130 crore, with an additional ₹110 crore as milestone-based consideration, aiming to expand its consumer health vertical. - IMPACT: While this acquisition focuses on consumer wellness, it may allow Cipla to reallocate resources, potentially affecting its pharmaceutical exports, including Celecoxib.
Impact: While this acquisition focuses on consumer wellness, it may allow Cipla to reallocate resources, potentially affecting its pharmaceutical exports, including Celecoxib.
Akums Drugs and Pharmaceuticals Limited — Akums Drugs and Pharmaceuticals goes public
Akums Drugs and Pharmaceuticals Limited became publicly listed on August 6, 2024, marking a significant milestone in its corporate history. - IMPACT: The public listing may provide Akums with additional capital to expand its manufacturing capabilities, potentially impacting its production and export of pharmaceuticals, including Celecoxib.
Impact: The public listing may provide Akums with additional capital to expand its manufacturing capabilities, potentially impacting its production and export of pharmaceuticals, including Celecoxib.
Common Questions — Celecoxib Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which celecoxib supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, UMEDICA LABORATORIES PRIVATE LIMITED leads with 65 recorded shipments worth $24.8M. MACLEODS PHARMACEUTICALS LTD (184 shipments) and ALEMBIC PHARMACEUTICALS LIMITED (434 shipments) are also established high-volume exporters.
Q How many celecoxib manufacturers are there in India?
India has 326 active celecoxib exporters with a combined export market of $133.6M across 4,880 shipments to 112 countries. The top 5 suppliers hold 55.8% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for celecoxib from India?
Average FOB unit price: $4.39 per unit, ranging from $0.00 to $730.67. Average shipment value: $27.4K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 326 verified Indian exporters of Celecoxib ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 4,880 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 112 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
4,880 Verified Shipments
326 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists